Introduction: COVID-19 caused by a novel RNA virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first detected in December 2019 in Wuhan province of China and quickly spread all over the world. The most symptoms of the disease including loss of sense of smell and taste, shortness of breath, lethargy, cough and fever, vary from patient to patient. Several factors, including genetic susceptibility, can be associated with COVID-19 severity in different people. Single nucleotide polymorphisms (SNPs) are the most common type of genetic variation among people. Using SNPs, scientists can determine the severity of the disease in different people and develop drug candidates by assessing the genetic make-up of people who develop specific diseases. In this research, we are trying to find a biomarker in the MCP-1 gene to predict the severity of the disease in COVID-19 patients. Methods: According to previous studies, rs1024611 in MCP-1 gene was selected as a single nucleotide polymorphism associated with the severity of allergy and pulmonary diseases. 116 blood samples of patient with COVID-19 (PCR-positive) are used in three groups of outpatients, ICU patients and hospitalized patients. After DNA extraction, RFLP-PCR was done for rs1024611 in MCP-1 gene with PvuII restriction enzyme. Finally, the genetic data was analyzed using SPSS software, and t-test. Results: Based of the statistical analysis, there was no significant relationship between the rs1024611 polymorphism in the MCP-1 gene and the severity of the disease. Conclusion: Considering the high human and economic damage caused by the COVID-19 disease, it seems necessary to find predictive genetic and biochemical markers for detection of the susceptibility to the disease and its severity.
